297 related articles for article (PubMed ID: 26670200)
1. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.
Thiery-Vuillemin A; Cholley T; Calcagno F; Hugues M; Maurina T; Limat S; Nguyen Tan Hon T; Almotlak H; Mouillet G; Nerich V
Clin Genitourin Cancer; 2018 Apr; 16(2):e297-e305. PubMed ID: 29066073
[TBL] [Abstract][Full Text] [Related]
4. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37813745
[TBL] [Abstract][Full Text] [Related]
5. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
6. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
7. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
8. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
9. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
[TBL] [Abstract][Full Text] [Related]
17. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
18. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
[TBL] [Abstract][Full Text] [Related]
19. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
20. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]